Research hub
Everything Stocknote has published on Value Investing: 3 research articles covering 3 companies across 2 categories. The latest piece was published on June 14, 2026.
Conagra's 11% dividend yield is pricing in a B&G Foods-style halving — but Conagra runs at 3.8x leverage versus B&G's 6-8x, and Q3 organic sales just returned to growth led by Frozen and Snacks.
PYPL has de-rated to ~$44 and ~8.4x earnings on a single fear — branded checkout is losing share — while consensus misprices three things the filings refute: a ~$14B transaction-profit base growing 3% in spite of the checkout drag, a Venmo/PSP growth engine compounding double digits, and a ~$6B annual buyback retiring ~10% of the float a year. Forensic case: BUY, $62 in 12 months, $80+ long-term.
Altria has re-rated 27% to ~$72, yet still trades at 13x against a 19x historical average while consensus prices three demonstrably wrong calls: a "volume cliff" offset by relentless pricing power, a smoke-free option marked near zero after NJOY, and a ~$9B ABI stake buried by single-multiple math. Forensic case: BUY, $82 in 12 months, $95+ long-term.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
